<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03634059</url>
  </required_header>
  <id_info>
    <org_study_id>HRA-L01</org_study_id>
    <nct_id>NCT03634059</nct_id>
  </id_info>
  <brief_title>A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations</brief_title>
  <official_title>A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University Fourth Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of apatinib plus EGFR-TKI as
      first line treatment in patients with non-squamous NSCLC harboring EGFR mutation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2018</start_date>
  <completion_date type="Anticipated">August 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>evaluated in two years since the treatment began</time_frame>
    <description>Baseline to measured date of progression or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>tumor assessment every 8 weeks，up to two years</time_frame>
    <description>Baseline to measured stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>tumor assessment every 8 weeks，up to two years</time_frame>
    <description>Baseline to measured progressive disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>the first day of treatment to death or last survival confirm date，up to two years</time_frame>
    <description>Baseline to measured date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>evaluated in the two years since the treatment began according to the Common Terminology Criteria for Adverse Events Version 4.0</time_frame>
    <description>throughout study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po</description>
    <arm_group_label>apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age:18 to 75 years old (man or female);

          2. Pathologically diagnosed with non-squamous NSCLC;

          3. Imageology diagnosed with locally advanced/metastatic or recurrent (stage ⅢB - IV);

          4. Histologically or cytologic confirmed，harboring an activating EGFR mutation (19del or
             21 L858R);

          5. None previous chemotherapy or targeted therapy.（NOTE: neoadjuvant and adjuvant therapy
             is allowed）;

          6. At least one measurable lesion (measuring≥10mm on spiral CT scan, satisfying the
             criteria in RECIST1.1)；

          7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;

          8. Major organ function has to meet the following criteria:

               1. HB≥90g/L；

               2. ANC≥1.5×109/L；

               3. PLT≥80×109/L；

               4. ALT and AST≤2.5ULN, but≤5ULN if the transferanse elevation is due to liver
                  metastases;

               5. TBIL≤1.5ULN;

               6. Serum creatinine≤1.25ULN; Endogenous creatinine clearance rate＞45 ml/min;

          9. Life expectancy greater than or equal to 3 months;

         10. Women of childbearing age must have contraceptive measures or have test pregnancy
             (serum or urine) enroll the study before 7 days, and the results must be negative, and
             take the methods of contraception during the test and the last to have drugs after 8
             weeks. Men must be contraception or has sterilization surgery during the test and the
             last to have drugs after 8 weeks;

         11. Participants were willing to join in this study, and written informed consent, good
             adherence, cooperate with the follow-up.

        Exclusion Criteria:

          1. Have high blood pressure and antihypertensive drug treatment can not control (systolic
             blood pressure &gt; 140 mmHg, diastolic blood pressure &gt; 90 mmHg);

          2. Patients who suffered from grade II or above myocardial ischemia or myocardial
             infarction, uncontrolled arrhythmias (including QT interval male ≥ 450 ms, female ≥
             470 ms). Grade III-IV cardiac insufficiency according to New York Heart
             Association(NYHA) criteria or echocardiography check: left ventricular ejection
             fraction (LVEF)&lt;50%;

          3. Radiologically documented evidence of major blood vessel invasion or encasement by
             cancer;

          4. A variety of factors influencing oral drugs (such as unable to swallow, nausea,
             vomiting, chronic diarrhea and intestinal obstruction, etc);

          5. Patients with tendency of gastrointestinal bleeding, including the following: a local
             active ulcerative lesions, and defecate occult blood (++). Has melena and hematemesis
             in two months;

          6. Coagulant function abnormality (INR &gt; 1.5 ULN, APTT &gt; 1.5 ULN), with bleeding
             tendency;

          7. Patients with pregnant or planning a pregnancy;

          8. Patients with other malignant tumors within 5 years (except for the treated skin basal
             cell carcinoma and cervical carcinoma in situ);

          9. History of psychiatric drugs abuse and can't quit or patients with mental disorders;

         10. Less than 4 weeks from the last clinical trial;

         11. The researchers think inappropriate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junfeng Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Medical University Fourth Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junfeng Liu, Professor</last_name>
    <phone>13931152296</phone>
    <email>13931152296@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Junfeng Liu</last_name>
    <phone>13931152296</phone>
    <email>13931152296@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Junfeng Liu</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Junfeng Liu, Professor</last_name>
      <phone>13931152296</phone>
      <email>13931152296@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>August 14, 2018</last_update_submitted>
  <last_update_submitted_qc>August 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University Fourth Hospital</investigator_affiliation>
    <investigator_full_name>LiuJunFeng</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

